37.16
+0.33(+0.90%)
Currency In USD
| Previous Close | 36.83 |
| Open | 37.13 |
| Day High | 37.48 |
| Day Low | 36.03 |
| 52-Week High | 60.37 |
| 52-Week Low | 29.59 |
| Volume | 866,700 |
| Average Volume | 1.02M |
| Market Cap | 3.51B |
| PE | -6.37 |
| EPS | -5.83 |
| Moving Average 50 Days | 36.41 |
| Moving Average 200 Days | 43.93 |
| Change | 0.33 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $372.23 as of June 25, 2025 at a share price of $37.16. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $479.3 as of June 25, 2025 at a share price of $37.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 03, 2025 9:00 PM GMT
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
GlobeNewswire Inc.
May 14, 2025 8:30 PM GMT
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report highlights efforts to transform the li
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
GlobeNewswire Inc.
May 07, 2025 9:00 PM GMT
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today